Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein that binds heparan sulfate proteoglycans, where the AAV virions exhibit greater infectivity of retinal cells, altered tropism and/or the ability to bind and cross the inner limiting membrane following intravitreal injection. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.

Abstract: The present disclosure provides proteins that bind lanthanides and actinides. Disclosed are proteins based on lanmodulin (LanM) that comprised one or more sensitizers. Various residues in LanM may be substituted with a sensitizer, such as, for example, tryptophan. The proteins may be used to detect and quantify lanthanides and actinides. Also provided are kits and devices.

Abstract: The present invention provides a Mnep monomer variant including an amino acid sequence with any one or more amino acid mutations at positions 92-104 of SEQ ID NO: 1, a porin or construct including at least one Mnep monomer variant, and a use thereof. The present invention also provides a method for characterizing a target polynucleotide.

Abstract: An excellent photosensitivity is exhibited by a protein including, at a position or positions corresponding to one or two or more positions selected from the group made of the following (1) to (3) in a first amino acid sequence represented by SEQ ID NO: 1: (1) positions 39, 94, 98, 102, 110, 113, 114, 162, 224, 225, 230, 231, and 235, (2) positions 53, 61, 68, 74, 76, 80, 130, 137, 194, 195, 198, 200, 204, 205, 209, 210, 253, and 254, and (3) positions 46, 83, 84, 87, 90, 91, 116, 117, 120, 124, 139, 142, 143, 146, 173, 214, 216, 217, 238, 242, and 245, an amino acid residue different from that in the first amino acid sequence, and that has channel activity.

Abstract: The disclosure relates to novel soybean plants, plant parts, and nucleotide sequences in soybean plants comprising a mutated FT1a and other genes, along with methods of using and making the same.

Abstract: The present disclosure relates to the technical field of genetic engineering, and in particular to a use of a Glycine max GmSAMMT gene in regulation of a protein content and/or a yield of a plant. The present disclosure has proved through experiments that an expression level of the GmSAMMT gene in a GmSAMMT-knockout line is significantly lower than an expression level of the GmSAMMT gene in a control line, and a protein content and a seed weight of a GmSAMMT-knockout line are significantly higher than a protein content and a seed weight of a control line. Compared with the control line, in a GmSAMMT-overexpressed line, a transcription level of the GmSAMMT gene is significantly increased, a protein content is significantly reduced, and a seed weight is also reduced without a significant difference.

Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.

Abstract: The present invention relates to an acidic formulation comprising a silk polypeptide and formate. The present invention further relates to a method for producing said formulation. The present invention also relates to the uses of said formulation.

Abstract: A method for preparing a controllable high-concentration silk fibroin solution with high molecular weight using tangential flow ultrafiltration technology is provided. It includes steps of acquiring an inorganic salt solution of silk fibroin; subjecting the inorganic salt solution of silk fibroin to membrane clarification process; desalting the inorganic salt solution of silk fibroin by filtering the clarified solution obtained from the membrane clarification process through a tangential flow filtration system; and concentrating the silk fibroin solution to give a high-concentration aqueous solution of silk fibroin with high molecular weight. The method accomplishes the desalination and concentration of a salt solution of silk fibroin by the tangential flow filtration technology, and directly acquires an aqueous solution of silk fibroin with a number-average molecular weight of 80 kDa-200 kDa.

Abstract: Provided herein are methods for treating a disease or disorder associated with mitochondrial dysfunction through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. The nucleic acid molecule may include a functional human frataxin (hFXN) or may include a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN.

Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

Abstract: Described herein is a recombinant Eomes protein that restores the cytotoxic activity of exhausted immune cells. This protein comprises, a nuclear localization sequence (NLS), the transcription factor associated domain of Eomesodermin (Eomes), and a protein-transduction domain (PTD). The NLS-Eomes-PTD polypeptide spontaneously internalizes into NK cells and travels to the nucleus to control the transcription of its down-stream signaling pathways. Introduction of the NLS-Eomes-PTD polypeptide into ExNK cells (i) decreases the expression of an inhibitory antigen on ExNK cells; (ii) increases cytolytic activity: (iii) enhances cytokine secretion; (iv) improves proliferation; and (v) inhibits tumor growth.

Abstract: Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation.

Abstract: The disclosure provides cardiac cell-specific enhancer sequences. The enhancers are specific to cardiac cells, such as cardiac fibroblasts. Also provided are polynucleotides, vectors, cells, compositions and kits, and methods of use thereof.

Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-?2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.

Abstract: Peptide analogues of dynorphin and their use in pain management, the peptide analogues having good biological stability and reduced side effects compared to opioid analgesics.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.

Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs). T-cells engineered to express one or more TFPs. and methods of use thereof for the treatment of diseases, including cancer.

Abstract: Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a MAGE-A4 positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 10-20 ?g; (b) at least one second dose in the range of from 40-50 ?g; and then (c) at least one third dose in the range of from 90-400 ?g, wherein doses are administered every 6-8 days.

Abstract: Polypeptides comprising: (i) an MHC class I ? polypeptide association domain, (ii) a transmembrane domain, and (iii) a signalling domain comprising an ITAM-containing sequence are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using such polypeptides.

Abstract: The present disclosure provides methods and compositions for affinity purification of proteins containing a C-terminal polypeptide sequence of a procollagen, such as trimeric fusion proteins. Also provided are polypeptides, fusion proteins, and recombinant polypeptides containing an Endo 180 ecto-domain or portion thereof capable of reversibly binding a C-terminal polypeptide sequence of a procollagen. Also provided are articles of manufacture, kits, and apparatus related to the Endo 180 ecto-domain polypeptides.

Abstract: The present invention concerns a polynucleotide construct encoding a mini-receptor of SORLA. The present invention further concerns a vector, a cell and/or a composition comprising said polynucleotide construct. The present invention further concerns a polypeptide representing a mini-receptor of SORLA. The present invention further concerns said vector, said cell and/or said composition comprising said poly nucleotide construct, for use in medicine. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in treatment, prevention and/or alleviation of Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of treating Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of increasing sAPP? in a cell.

Abstract: The present application relates to a truncated TACI polypeptide and a fusion protein and use thereof. Specifically, provided are a TACI polypeptide as shown in SEQ ID NO: 8, a truncated fragment thereof, a mutation sequence thereof, and a fusion protein comprising the TACI polypeptide and use thereof.

Abstract: The disclosure is directed towards polypeptide substrates and methods of synthesis thereof. Such substrates can be embedded with calcium ions from a number of ionic sources. These calcium-embedded, polypeptide substrates can be used to grow a variety of crystal structures including flower-shaped, onion-shaped, and needle-like crystal structures. As such, the disclosure is additionally directed towards methods of crystal growth from polypeptide substrates. Compositions of the disclosure can be used in a wide variety of medical and other applications.

Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

Abstract: Described herein are compositions of therapeutic extracellular vesicles, and methods and systems of producing the therapeutic extracellular vesicles. Also described herein are methods of treating a disease or condition with the therapeutic extracellular vesicles.

Abstract: Provided is a polypeptide, a production method therefor and a use thereof. The polypeptide includes 63 to 1496 continuous amino acid residues of SEQ ID NO: 9, and includes a sequence represented by (A)m or is composed of the sequence represented by (A)m, wherein each A is an amino acid sequence selected from any one of those represented by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, or a modified amino acid sequence or a sequence variant thereof; m is an integer between 1 and 10; and each A is the same or different and two adjacent As are directly connected by peptide bonds or connected by at least one amino acid residue, wherein the polypeptide has a cell adhesion activity, and a method of producing said polypeptide and use of said polypeptide.

Abstract: A process is provided for inhibiting symptoms or correction of gastrointestinal antibody deficiency in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled polyclonal human plasma derived dimeric and polymeric. When administered in a therapeutic quantity, symptoms of intestinal lumen antibody deficiency in the subject are inhibited or prevented.

Abstract: Compositions and methods are disclosed for treating and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus spike protein or mutants thereof.

Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

Abstract: The invention provides nanobodies that bind with high affinity to SARS-CoV-2 non-structural protein (Nsp), as well and compositions comprising the identified nanobodies and methods of use thereof to block activation of SARS-CoV-2 viral replication, and for the treatment or prevention of COVID-19.

Abstract: The present invention relates to an antibody directed against HERV-W envelope protein (ENV) for use in the treatment of a group of patients diagnosed with a psychotic disease and characterized with a high level for a cytokine in a body fluid sample.

Abstract: Speciated antibodies or antigen-binding fragments that bind staphylococcal antigens are provided, where the antibodies and antigen-binding fragments have attenuated Fc binding to Protein A or homologous protein. Compositions comprising the antibodies and methods of use are also provided. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or kidney bacterial titers, and treating symptoms associated with staphylococcal infection. The antibodies may also prevent the severity and/or duration of the primary disease.

Abstract: The invention provides methods and compositions for treating or ameliorating Alzheimer's disease. The invention provides agents that reduce A? inclusions and plaque accumulation, inhibit dendrite spine loss, and restore neurogenesis.

Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Abstract: Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.

Abstract: The present invention is directed to providing a monoclonal antibody having high selectivity and affinity for AGEs, particularly, AGEs derived from glyceraldehyde or AGEs derived from glycolaldehyde, and an analysis method utilizing the same. Another object of the present invention is to provide methods for diagnosing, treating and preventing a disease using the monoclonal antibody.

Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).

Abstract: Methods and diagnostic compositions for detection of amyloid deposits using a chimeric (e.g., mouse-human) antibody or antigen-binding fragment thereof linked to a detectable label are disclosed.

Abstract: Disclosed are compositions and methods related to anti-IL-17A antibodies and antigen binding fragments thereof. Additionally provided are bi-specific binding proteins comprising the anti-IL-17A binding domains. Additionally provided are methods of use for the compounds and compositions described herein in the treatment of inflammatory diseases and ocular disorders.

Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.

Abstract: The present invention relates to a novel binding molecule with excellent preventive, ameliorative or therapeutic effects on a brain and nervous system disease and uses thereof. The binding molecule provided in the present invention can effectively prevent or treat brain and nervous system diseases, particularly neurodegenerative diseases or neuroinflammatory diseases.

Abstract: The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CLDN6, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human solute carrier 34 A2 (SLC34A2) protein. These antibodies are capable of binding to SLC34A2 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC) and effectively induce endocytosis. Also provided are methods and uses for treating cancers.

Abstract: Combination therapies comprising TIM-3 inhibitors are disclosed. The combinations can be used to treat cancerous conditions and disorders, including hematologic cancers.

Abstract: Maintenance therapies comprising TIM-3 inhibitors are disclosed. The maintenance therapies can be used to treat cancerous conditions and disorders, including hematologic cancers. Maintenance therapies comprising TIM-3 inhibitors are also disclosed.

Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.

Abstract: The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.

Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.